Vaccine therapy for melanoma: Current status and future directions

Vaccine

Volumn 25, Issue SUPPL. 2, 2007, Pages

  Terando, Alicia M ^a   Faries, Mark B ^a   Morton, Donald L ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

Cancer vaccines; Immunotherapy; Melanoma

Indexed keywords

2,4 DINITROPHENOL; ADENOVIRUS VECTOR; ALPHA INTERFERON; ALUMINUM HYDROXIDE; ALUMINUM POTASSIUM SULFATE; ANTINEOPLASTIC AGENT; BCG VACCINE; CANCER VACCINE; CANVAXIN; CPG OLIGODEOXYNUCLEOTIDE; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DENDRITIC CELL VACCINE; GANGLIOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMIDAZOQUINOLINE DERIVATIVE; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; M VAX; MELACINE; MELANOMA VACCINE; MONOCLONAL ANTIBODY; PHOSPHORYL LIPID A; PLASMID DNA; PROSTAGLANDIN E2; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADJUVANT THERAPY; ANTIGEN SPECIFICITY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELLULAR IMMUNITY; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; HLA SYSTEM; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; LOW DRUG DOSE; LYMPHOCYTE DEPLETION; MELANOMA; PRIORITY JOURNAL; REVIEW; STATISTICAL SIGNIFICANCE; TUMOR IMMUNITY;

ANIMALS; CANCER VACCINES; HUMANS; IMMUNOTHERAPY; MELANOMA; SKIN NEOPLASMS;

EID: 34748849509     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.06.033     Document Type: Review

References (88)

1. DeMatos P., Abdel-Wahab Z., Vervaert C., Hester D., and Seigler H. Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice. J Surg Oncol 68 2 (1998) 79-91
2. Berd D., Maguire Jr. H.C., and Mastrangelo M.J. Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res 46 5 (1986) 2572-2577
3. Berd D., Maguire Jr. H.C., and Mastrangelo M.J. Treatment of human melanoma with a hapten-modified autologous vaccine. Ann NY Acad Sci 690 (1993) 147-152
4. Berd D., Maguire Jr. H.C., Schuchter L.M., Hamilton R., Hauck W.W., Sato T., et al. Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. J Clin Oncol 15 6 (1997) 2359-2370
5. Berd D., Sato T., Maguire Jr. H.C., Kairys J., and Mastrangelo M.J. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J Clin Oncol 22 3 (2004) 403-415
6. Baars A., Claessen A.M., van den Eertwegh A.J., Gall H.E., Stam A.G., Meijer S., et al. Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma: experience in 81 patients. Ann Oncol 11 8 (2000) 965-970
7. Lotem M., Shiloni E., Pappo I., Drize O., Hamburger T., Weitzen R., et al. Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma. Br J Cancer 90 4 (2004) 773-780
8. Mitchell M.S., Kan-Mitchell J., Kempf R.A., Harel W., Shau H., and Lind S. Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res 48 (1988) 5883-5893
9. Mitchell M.S., Harel W., and Groshen S. Association of HLA phenotype with response to active specific immunotherapy of melanoma. J Clin Oncol 10 7 (1992) 1158-1164
10. Sondak V.K., Liu P.Y., Tuthill R.J., Kempf R.A., Unger J.M., Sosman J.A., et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol 20 8 (2002) 2058-2066
11. Sosman J.A., Unger J.M., Liu P.Y., Flaherty L.E., Park M.S., Kempf R.A., et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J Clin Oncol 20 8 (2002) 2067-2075
12. Hoon D.S., Okamoto T., Wang H.J., Elashoff R., Nizze A.J., Foshag L.J., et al. Is the survival of melanoma patients receiving polyvalent melanoma cell vaccine linked to the human leukocyte antigen phenotype of patients?. J Clin Oncol 16 4 (1998) 1430-1437
13. Morton D.L., Hsueh E.C., Essner R., Foshag L.J., O'Day S.J., Bilchik A., et al. Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes. Ann Surg 236 4 (2002) 438-448
14. Hsueh E.C., Essner R., Foshag L.J., Ollila D.W., Gammon G., O'Day S.J., et al. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol 20 23 (2002) 4549-4554
15. Sondak V.K., Sabel M.S., and Mulé J.J. Allogeneic and autologous melanoma vaccines: where have we been and where are we going?. Clin Cancer Res 12 7 Pt 2 (2006) 2337s-2341s
16. Rosenberg S.A., Packard B.S., Aebersold P.M., Solomon D., Topalian S.L., Toy S.T., et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 319 25 (1988) 1676-1680
17. Kawakami Y., Eliyahu S., Sakaguchi K., Robbins P.F., Rivoltini L., Yannelli J.R., et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 180 1 (1994) 347-352
18. Bakker A.B., Schreurs M.W., de Boer A.J., Kawakami Y., Rosenberg S.A., Adema G.J., et al. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med 179 3 (1994) 1005-1009
19. Lee K.H., Panelli M.C., Kim C.J., Riker A.I., Bettinotti M.P., Roden M.M., et al. Functional dissociation between local and systemic immune response during anti-melanoma peptide vaccination. J Immunol 161 8 (1998) 4183-4194
20. Bettinotti M.P., Panelli M.C., Ruppe E., Mocellin S., Phan G.Q., White D.E., et al. Clinical and immunological evaluation of patients with metastatic melanoma undergoing immunization with the HLA-Cw*0702-associated epitope MAGE-A12:170-178. Int J Cancer 105 2 (2003) 210-216
21. Maeurer M.J., Gollin S.M., Martin D., Swaney W., Bryant J., Castelli C., et al. Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J Clin Invest 98 7 (1996) 1633-1641
22. Pullarkat V., Lee P.P., Scotland R., Rubio V., Groshen S., Gee C., et al. A phase I trial of SD-9427 (progenipoietin) with a multipeptide vaccine for resected metastatic melanoma. Clin Cancer Res 9 4 (2003) 1301-1312
23. Phan G.Q., Touloukian C.E., Yang J.C., Restifo N.P., Sherry R.M., Hwu P., et al. Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens. J Immunother 26 4 (2003) 349-356
24. Slingluff Jr. C.L., Petroni G.R., Yamshchikov G.V., Hibbitts S., Grosh W.W., Chianese-Bullock K.A., et al. Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. J Clin Oncol 22 22 (2004) 4474-4485
25. Cebon J., Jager E., Shackleton M.J., Gibbs P., Davis I.D., Hopkins W., et al. Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma. Cancer Immun 3 (2003) 7
26. Scheibenbogen C., Schadendorf D., Bechrakis N.E., Nagorsen D., Hofmann U., Servetopoulou F., et al. Effects of granulocyte-macrophage colony-stimulating factor and foreign helper protein as immunologic adjuvants on the T-cell response to vaccination with tyrosinase peptides. Int J Cancer 104 2 (2003) 188-194
27. Di Pucchio T., Pilla L., Capone I., Ferrantini M., Montefiore E., Urbani F., et al. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors. Cancer Res 66 9 (2006) 4943-4951
28. Slingluff Jr. C.L., Yamshchikov G., Neese P., Galavotti H., Eastham S., Engelhard V.H., et al. Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin Cancer Res 7 10 (2001) 3012-3024
29. Wong R., Lau R., Chang J., Kuus-Reichel T., Brichard V., Bruck C., et al. Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma. Clin Cancer Res 10 15 (2004) 5004-5013
30. Rosenberg S.A., Yang J.C., and Restifo N.P. Cancer immunotherapy: moving beyond current vaccines. Nat Med 10 9 (2004) 909-915
31. Lee K.H., Wang E., Nielsen M.B., Wunderlich J., Migueles S., Connors M., et al. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J Immunol 163 11 (1999) 6292-6300
32. Rosenberg S.A., Yang J.C., Sherry R.M., Hwu P., Topalian S.L., Schwartzentruber D.J., et al. Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. Hum Gene Ther 14 8 (2003) 709-714
33. Tagawa S.T., Lee P., Snively J., Boswell W., Ounpraseuth S., Lee S., et al. Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma. Cancer 98 1 (2003) 144-154
34. Brinckerhoff L.H., Kalashnikov V.V., Thompson L.W., Yamshchikov G.V., Pierce R.A., Galavotti H.S., et al. Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: implications for peptide vaccines. Int J Cancer 83 3 (1999) 326-334
35. Rosenberg S.A., Zhai Y., Yang J.C., Schwartzentruber D.J., Hwu P., Marincola F.M., et al. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst 90 24 (1998) 1894-1900
36. van Baren N., Bonnet M.C., Dreno B., Khammari A., Dorval T., Piperno-Neumann S., et al. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J Clin Oncol 23 35 (2005) 9008-9021
37. Rosenberg S.A., Yang J.C., Schwartzentruber D.J., Hwu P., Topalian S.L., Sherry R.M., et al. Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma. Clin Cancer Res 9 8 (2003) 2973-2980
38. Lindsey K.R., Gritz L., Sherry R., Abati A., Fetsch P.A., Goldfeder L.C., et al. Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma. Clin Cancer Res 12 8 (2006) 2526-2537
39. Palmowski M.J., Choi E.M., Hermans I.F., Gilbert S.C., Chen J.L., Gileadi U., et al. Competition between CTL narrows the immune response induced by prime-boost vaccination protocols. J Immunol 168 9 (2002) 4391-4398
40. Livingston P.O., Wong G.Y., Adluri S., Tao Y., Padavan M., Parente R., et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 12 5 (1994) 1036-1044
41. Kirkwood J.M., Ibrahim J.G., Sosman J.A., Sondak V.K., Agarwala S.S., Ernstoff M.S., et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 19 9 (2001) 2370-2380
42. Faries M.B., and Morton D.L. Therapeutic vaccines for melanoma: current status. BioDrugs 19 4 (2005) 247-260
43. Matzinger P. The danger model: a renewed sense of self. Science 296 5566 (2002) 301-305
44. Mazzoni A., and Segal D.M. Controlling the Toll road to dendritic cell polarization. J Leukoc Biol 75 5 (2004) 721-730
45. Slingluff Jr. C.L., Petroni G.R., Yamshchikov G.V., Barnd D.L., Eastham S., Galavotti H., et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol 21 21 (2003) 4016-4026
46. Banchereau J., Ueno H., Dhodapkar M., Connolly J., Finholt J.P., Klechevsky E., et al. Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon. J Immunother 28 5 (2005) 505-516
47. Fay J.W., Palucka A.K., Paczesny S., Dhodapkar M., Johnston D.A., Burkeholder S., et al. Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells. Cancer Immunol Immunother 55 10 (2006) 1209-1218
48. Chang A.E., Redman B.G., Whitfield J.R., Nickoloff B.J., Braun T.M., Lee P.P., et al. A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin Cancer Res 8 4 (2002) 1021-1032
49. Palucka A.K., Ueno H., Connolly J., Kerneis-Norvell F., Blanck J.P., Johnston D.A., et al. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. J Immunother 29 5 (2006) 545-557
50. Gordon L.K., Ribas A., Nusinowitz S., Butterfield L.H., Glaspy J.A., Economou J.S., et al. Surveillance of the eye and vision in a clinical trial of MART1-transformed dendritic cells for metastatic melanoma. Control Clin Trials 25 4 (2004) 400-407
51. Kyte J.A., Mu L., Aamdal S., Kvalheim G., Dueland S., Hauser M., et al. Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. Cancer Gene Ther 13 10 (2006) 905-918
52. Trefzer U., Herberth G., Wohlan K., Milling A., Thiemann M., Sharav T., et al. Tumour-dendritic hybrid cell vaccination for the treatment of patients with malignant melanoma: immunological effects and clinical results. Vaccine 23 17/18 (2005) 2367-2373
53. Candido K.A., Shimizu K., McLaughlin J.C., Kunkel R., Fuller J.A., Redman B.G., et al. Local administration of dendritic cells inhibits established breast tumor growth: implications for apoptosis-inducing agents. Cancer Res 61 1 (2001) 228-236
54. Triozzi P.L., Khurram R., Aldrich W.A., Walker M.J., Kim J.A., and Jaynes S. Intratumoral injection of dendritic cells derived in vitro in patients with metastatic cancer. Cancer 89 12 (2000) 2646-2654
55. Jonuleit H., Kuhn U., Muller G., Steinbrink K., Paragnik L., Schmitt E., et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 27 12 (1997) 3135-3142
56. Grover A., Kim G.J., Lizee G., Tschoi M., Wang G., Wunderlich J.R., et al. Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes. Clin Cancer Res 12 19 (2006) 5801-5808
57. Bedrosian I., Mick R., Xu S., Nisenbaum H., Faries M., Zhang P., et al. Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients. J Clin Oncol 21 20 (2003) 3826-3835
58. Schadendorf D., Ugurel S., Schuler-Thurner B., Nestle F.O., Enk A., Brocker E.B., et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 17 4 (2006) 563-570
59. Schneeberger A., Luhrs P., Kutil R., Steinlein P., Schild H., Schmidt W., et al. Granulocyte-macrophage colony-stimulating factor-based melanoma cell vaccines immunize syngeneic and allogeneic recipients via host dendritic cells. J Immunol 171 10 (2003) 5180-5187
60. Soiffer R., Lynch T., Mihm M., Jung K., Rhuda C., Schmollinger J.C., et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci USA 95 22 (1998) 13141-13146
61. Luiten R.M., Kueter E.W., Mooi W., Gallee M.P., Rankin E.M., Gerritsen W.R., et al. Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients. J Clin Oncol 23 35 (2005) 8978-8991
62. Moller P., Moller H., Sun Y., Dorbic T., Henz B.M., Wittig B., et al. Increased non-major histocompatibility complex-restricted lytic activity in melanoma patients vaccinated with cytokine gene-transfected autologous tumor cells. Cancer Gene Ther 7 7 (2000) 976-984
63. Sun Y., Jurgovsky K., Moller P., Alijagic S., Dorbic T., Georgieva J., et al. Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study. Gene Ther 5 4 (1998) 481-490
64. Schreiber S., Kampgen E., Wagner E., Pirkhammer D., Trcka J., Korschan H., et al. Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: outcome of a phase I study. Hum Gene Ther 10 6 (1999) 983-993
65. Abdel-Wahab Z., Weltz C., Hester D., Pickett N., Vervaert C., Barber J.R., et al. A Phase I clinical trial of immunotherapy with interferon-gamma gene-modified autologous melanoma cells: monitoring the humoral immune response. Cancer 80 3 (1997) 401-412
66. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20 (2002) 709-760
67. Pilon-Thomas S., Li W., Briggs J.J., Djeu J., Mulé J.J., and Riker A.I. Immunostimulatory effects of CpG-ODN upon dendritic cell-based immunotherapy in a murine melanoma model. J Immunother 29 4 (2006) 381-387
68. Speiser D.E., Lienard D., Rufer N., Rubio-Godoy V., Rimoldi D., Lejeune F., et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 115 3 (2005) 739-746
69. Shackleton M., Davis I.D., Hopkins W., Jackson H., Dimopoulos N., Tai T., et al. The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer Immun 4 (2004) 9
70. Terando A., and Mulé J.J. On combining antineoplastic drugs with tumor vaccines. Cancer Immunol Immunother 52 11 (2003) 680-685
71. Asavaroengchai W., Kotera Y., and Mulé J.J. Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery. Proc Natl Acad Sci USA 99 2 (2002) 931-936
72. Dudley M.E., Wunderlich J.R., Yang J.C., Hwu P., Schwartzentruber D.J., Topalian S.L., et al. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother 25 3 (2002) 243-251
73. Shimizu J., Yamazaki S., and Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 163 10 (1999) 5211-5218
74. Sutmuller R.P., van Duivenvoorde L.M., van Elsas A., Schumacher T.N., Wildenberg M.E., Allison J.P., et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 194 6 (2001) 823-832
75. Attia P., Maker A.V., Haworth L.R., Rogers-Freezer L., and Rosenberg S.A. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J Immunother 28 6 (2005) 582-592
76. Dannull J., Su Z., Rizzieri D., Yang B.K., Coleman D., Yancey D., et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 115 12 (2005) 3623-3633
77. Machiels J.P., Reilly R.T., Emens L.A., Ercolini A.M., Lei R.Y., Weintraub D., et al. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res 61 9 (2001) 3689-3697
78. Berd D., Maguire Jr. H.C., and Mastrangelo M.J. Potentiation of human cell-mediated and humoral immunity by low-dose cyclophosphamide. Cancer Res 44 11 (1984) 5439-5443
79. Polak L., Geleick H., and Turk J.L. Reversal by cyclophosphamide of tolerance in contact sensitisation. Tolerance induced by prior feeding with DNCB. Immunology 28 5 (1975) 939-942
80. Waterhouse P., Penninger J.M., Timms E., Wakeham A., Shahinian A., Lee K.P., et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270 5238 (1995) 985-988
81. Hodi F.S., Mihm M.C., Soiffer R.J., Haluska F.G., Butler M., Seiden M.V., et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 100 8 (2003) 4712-4717
82. Robinson M.R., Chan C.C., Yang J.C., Rubin B.I., Gracia G.J., Sen H.N., et al. Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. J Immunother 27 6 (2004) 478-479
83. Wang F., Bade E., Kuniyoshi C., Spears L., Jeffery G., Marty V., et al. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Clin Cancer Res 5 10 (1999) 2756-2765
84. Scheibenbogen C., Schmittel A., Keilholz U., Allgauer T., Hofmann U., Max R., et al. Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma. J Immunother 23 2 (2000) 275-281
85. Jager E., Gnjatic S., Nagata Y., Stockert E., Jager D., Karbach J., et al. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci USA 97 22 (2000) 12198-12203
86. Tanaka S., Harada M., Mine T., Noguchi M., Gohara R., Azuma K., et al. Peptide vaccination for patients with melanoma and other types of cancer based on pre-existing peptide-specific ctotoxic T-lymphocyte precursors in the periphery. J Immunother 26 4 (2003) 357-366
87. Khong H.T., Yang J.C., Topalian S.L., Sherry R.M., Mavroukakis S.A., White D.E., et al. Immunization of HLA-A*0201 and/or HLA-DPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen. J Immunother 27 6 (2004) 472-477
88. Hamid O., Solomon J.C., Scotland R., Garcia M., Sian S., Ye W., et al. Alum with interleukin-12 augments immunity to a melanoma peptide vaccine: correlation with time to relapse in patients with resected high-risk disease. Clin Cancer Res 13 1 (2007) 215-222